Marshall Wace
PASG icon

Marshall Wace’s Passage Bio PASG Stock Holding History

Marshall Wace’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,100
Closed -$29.7K – 2851
2024
Q1 		$29.7K Buy
+1,100
New +$26.5K ﹤0.01% 2364
2022
Q4 		– Sell
-9,683
Closed -$242K – 3300
2022
Q3 		$242K Buy
9,683
+427
+5% +$16.8K ﹤0.01% 3025
2022
Q2 		$438K Sell
9,256
-689
-7% -$32.2K ﹤0.01% 2853
2022
Q1 		$616K Buy
9,945
+8,648
+667% +$713K ﹤0.01% 2680
2021
Q4 		$165K Sell
1,297
-2,249
-63% -$367K ﹤0.01% 3228
2021
Q3 		$705K Sell
3,546
-6,100
-63% -$1.45M ﹤0.01% 2219
2021
Q2 		$2.56M Sell
9,646
-6,148
-39% -$1.9M 0.01% 1249
2021
Q1 		$5.52M Buy
+15,794
New +$6.74M 0.03% 775

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace's PASG Position: Q2 2024 in Review

Marshall Wace sold out of Passage Bio (PASG) in Q2 2024, closing a stake of 1,100 shares — an estimated $29.7K sold.

Marshall Wace first reported a position in PASG in Q1 2021 and held it in 8 quarters. The position peaked at $5.52M in Q1 2021. 43 funds tracked by Wall St. Rank hold PASG as of Q2 2024.

  • Marshall Wace reported no remaining Passage Bio position as of Q2 2024 after selling out during the quarter.
  • Marshall Wace sold 1,100 Passage Bio shares in Q2 2024, an estimated $29.7K.
  • Marshall Wace first reported a position in Passage Bio in Q1 2021 and held it in 8 quarters.
  • Marshall Wace's Passage Bio position peaked at $5.52M in Q1 2021.
  • 43 funds tracked by Wall St. Rank held Passage Bio as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.